Study warns of danger of combining spironolactone and ACE inhibitors in heart patients

doi:10.1136/bmj.329.7463.420-e

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Scott Gottlieb

New York

The diuretic spironolactone can cause dangerous hyperkalaemia in patients who are also taking angiotensin converting enzyme (ACE) inhibitors, another drug that, like spironolactone, is used to treat congestive heart failure.

After the publication of a major heart study that promoted the use of spironolactone, prescribing rose, but so did cases of hyperkalaemia, according to Dr David Juurlink, a clinical pharmacologist at the University of Toronto and author of a new study that found a threefold increase in the rates of admission to hospital for high potassium levels across Ontario and a twofold increase in deaths involving high potassium levels (New England Journal of Medicine 2004;351:543-51).

The randomised aldactone evaluation study (RALES), which was reported in 1999, found …